Rapamycin: the strongest mouse story is still a human question.

Why mTOR attracts longevity researchers

Rapamycin, also called sirolimus, inhibits a nutrient-sensing pathway involved in cellular growth and maintenance. The appeal is broader than treating one disease: could changing this signalling reduce several age-related problems together? The challenge is that growth and repair also require well-timed anabolic signalling. An intervention can act on an ageing-related pathway without producing a net benefit in a whole person. [1]

Ethernia’s question is therefore specific: which exposure, in which population, improves a meaningful outcome? “mTOR inhibition works” leaves those essential details unanswered.

Animals: actual survival, not a clock score

Harrison and colleagues began feeding rapamycin to genetically heterogeneous mice at 600 days of age. Survival increased at three test sites. At the age corresponding to 90% mortality, the increase was 14% in females and 9% in males. These are mouse survival results using a particular endpoint; they are not percentages that can be applied to a human’s remaining years. [1]

Humans: two trials worth reading together

PEARL analysed 114 completers over 48 weeks. Its primary outcome, visceral adipose tissue, did not improve significantly. Some secondary results favoured treatment, particularly lean tissue and pain measures in women. Authors disclosed employment and shareholding in AgelessRx. Subgroup signals deserve replication rather than being treated as confirmation of general rejuvenation. [2]

The 2026 RAPA-EX-01 trial randomised 40 adults aged 65–85 alongside exercise. The primary chair-stand comparison was −2.13 repetitions for sirolimus versus placebo (95% CI −4.61 to 0.34; p=0.089). It did not demonstrate an added benefit. Sensitivity analyses favoured placebo; the small trial also recorded more adverse events with sirolimus. These findings do not settle every regimen, but they challenge the assumption that adding rapamycin automatically improves training outcomes. [3]

Exposure studied—and why formulation matters

PEARL studied compounded 5 mg or 10 mg once weekly; the paper reported lower blood exposure from its formulation than from commercial rapamycin. RAPA-EX studied 6 mg weekly for 13 weeks. These describe research exposures, not a recommended schedule. Milligrams alone are an incomplete comparison when formulation, drug interactions and tissue exposure differ. [2] [3]

The risks that belong in the calculation

The prescribing information describes infection susceptibility, impaired wound healing, lipid abnormalities, mouth ulcers and clinically important CYP3A4/P-glycoprotein interactions. Transplant regimens do not provide a direct risk estimate for intermittent use in healthy adults. Conversely, a small, short trial cannot exclude uncommon harms or establish safety over decades. Prescription use for a clinical indication and experimental longevity use answer different questions. [4]

Trials to watch

In March 2026, UT Health San Antonio described a programme comparing dosing approaches, including a planned approximately 84-person cohort with six months of treatment and six months of follow-up. This is a university trial announcement, not an efficacy result. The original PEARL registration remains useful for comparing planned endpoints with published findings. Recruitment and timelines should be checked at the source. [5] [6]

What would change the assessment?

An independently replicated, adequately powered trial showing less disability, fewer age-related clinical events or durable improvement in function would materially strengthen the human case. A change in a methylation score alone would leave a larger inference to make. The most valuable next trial would measure target engagement, predefine its primary outcome, report withdrawals and harms, and examine whether benefits persist. Human lifespan extension remains a separate, unanswered test.